drugset / Press release
Clinical Phase II of SOM0226 for transthyretin amyloidosis
2014-04-17 · SOM Innovation Biotech SA · original sombiotech.com ↗
SOM Biotech and The Vall d’Hebron Institute of Research (VHIR) have signed an agreement to jointly develop the clinical Phase II of SOM0226 drug for transthyretin Amyloidosis (ATTR).
The release as fetched from its publisher. sombiotech.com ↗